Clinical trial
Optimizing Prograf® Therapy in Renal Transplant Patients
NCT00297765 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00297765 |
|---|---|
| Title | Optimizing Prograf® Therapy in Renal Transplant Patients |
| Official title | OPTIMA (Optimizing Prograf® Therapy in Renal Transplant Patients) |
| Acronym | OPTIMA |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Renal Transplantation |
| Intervention type | Drug |
| Interventions | Tacrolimus, Prograf® |
| Enrollment | 323 |
| Start date | Jan 1, 2003 |
| Completion | Mar 1, 2006 |
| First posted | Mar 1, 2006 |
| Last update posted | Aug 26, 2008 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: